Multiple Drug Hypersensitivity Syndrome in a Large Database.

J Allergy Clin Immunol Pract

Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, University of Montpellier, Montpellier, France; Equipe EPAR-IPLESP, Sorbonne Université, Paris, France. Electronic address:

Published: January 2020

AI Article Synopsis

  • - Multiple Drug Hypersensitivity Syndrome (MDHS) is defined as confirmed drug allergies to at least two unrelated medications, but there's limited research on its prevalence and characteristics.
  • - In a study analyzing data from an Allergy Unit between 1996 and 2018, 45 patients were confirmed to have MDHS, with a significant portion linked to immunologic mechanisms and categorized into types IV and I allergies.
  • - The findings highlight MDHS as a rare condition, making up only 2.5% of patients with suspected drug hypersensitivity, emphasizing the need for skin testing and drug provocation tests for accurate diagnosis.

Article Abstract

Background: Multiple drug hypersensitivity syndrome (MDHS) is defined as confirmed drug hypersensitivity (DH) to at least 2 chemically and pharmacologically unrelated drugs. Reports of MDHS are scarce and poorly specified, and studies that diagnose MDHS on the basis of positive allergy test results are lacking.

Objective: To evaluate retrospectively the frequency and characteristics of patients with MDHS in a large database.

Methods: We included all patients who consulted and were tested in our Allergy Unit between September 1996 and February 2018 for a suspicion of DH. Clinical history and allergy workup results compiled in our Drug Allergy and Hypersensitivity Database were reviewed, and data of patients with a diagnosis of MDHS were retrieved and analyzed.

Results: During this period a total of 9250 patients were explored and 1819 tested positive for at least 1 drug. Forty-five cases, 30 female and 15 male patients cumulating 92 DHs, were confirmed as having MDHS. An immunologic mechanism, as demonstrated by positive skin testing, accounted for 59 DHs. Drug provocation tests were performed to confirm the diagnosis for the remaining 33 DHs. Of the 92 DHs in this series, 38 were classified as type IV and 21 as type I allergies; 33 remained of undetermined mechanism. Drug class occurrences seem to differ from those in monoallergic patients.

Conclusions: Our data support the concept of MDHS as a distinct and rare subgroup of DH. The prevalence in our database was 2.5% in the total DH alleged patient population and 0.5% of the demonstrated DHs. Skin testing and drug provocation tests are mandatory for confirming the diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.06.009DOI Listing

Publication Analysis

Top Keywords

drug hypersensitivity
12
multiple drug
8
hypersensitivity syndrome
8
skin testing
8
drug provocation
8
provocation tests
8
drug
7
mdhs
7
patients
5
dhs
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!